Roots Analysis
AUGUST 16, 2023
The success of COVID-19 vaccines paved the path for mRNA-based drug products. However, synthesis and manufacturing of mRNA is fraught with several challenges as the production of such biomolecules is complex, cost intensive, requires specialized expertise and dedicated equipment.
Pharmaceutical Technology
JULY 29, 2022
Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. In preparation for this, drug manufacturing will begin later this year and will be outsourced to external contract manufacturing organisations (CMOs).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 27, 2020
US biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury in severe COVID-19 patients, after concluding the safety of the combination was in doubt. Moreover, as an orally-active drug merimepodib could also have found a role outside the hospital setting.
pharmaphorum
JANUARY 6, 2021
Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases. Danish drugmaker Novo Nordisk signed a deal with the US biotech in 2019 valued at up to $675.5
Roots Analysis
FEBRUARY 21, 2022
These kits require less input sample, produce sufficient DNA / RNA libraries with minimum errors and are compatible with a broad range of input samples, including blood, cells, plasma and saliva. As per our analysis, majority of the kits use purified RNA / DNA as the input sample. Nanoparticles Contract Manufacturing.
Roots Analysis
FEBRUARY 18, 2022
In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. These contract service providers are actively entering into strategic collaborations to augment their existing portfolios.
The Pharma Data
NOVEMBER 19, 2021
Food and Drug Administration (FDA). ” PF-07321332 is designed to block the exertion of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate, at a stage known as proteolysis-which occurs before viral RNA replication. Pfizer moment blazoned an agreement with theU.S.
Expert insights. Personalized for you.
52 
Let's personalize your content